Drug Safety-related Labeling Changes (SrLC)

Get Email Alerts | Guide

Drug Safety-related Labeling Changes (SrLC) Database

ANDA	Abbreviated New Drug Application
BLA	Biologics License Application
CDER	Center for Drug Evaluation and Research
MG	Medication Guide
NDA	New Drug Application
PCI	Patient Counseling Information
PI	Patient Information
PLR	Physician Labeling Rule
PLLR	Pregnancy and Lactation Labeling Rule
Italics	For the most part, italics indicate an FDA comment such as: Additions and/or revisions underlined These italics usually appear at the beginning of the section. In some cases, italics may be an inherent part of the label, and will most often appear in the body of the section.
Underlines	Any text that is underlined indicates text that has been added or revised. There are exceptions where underlining occurs in a section subtitle or heading. This is the case when there is just one word underlined in the body of the text.

Sections

BW	Box Warning
WP	Warnings and Precautions all in one section (PLR-format) Warnings as one section (pre-PLR format) Precautions as one section (pre-PLR format)
AR	Adverse Reactions (in pre-PLR format, this may be a subheading under precautions).
DI	Drug Interactions (in pre-PLR format, this may be a subheading under precautions).
USP	Use in Specific Populations (Inclusive on one or more of the following: Pregnancy; Lactation (PLLR- format); Nursing Mothers (pre-PLLR format); Females and Males of Reproductive Potential (PLLR format only); Pediatric Use, Geriatric Use, Renal Impairment, Hepatic Impairment, Sex, Race (these last six may be a subheading of precautions if label in pre-PLLR format.
PCI/PI/MG	Patient Counseling Information (PLR format only) - summarizes the information that a health care provider should convey to a patient (or caregiver when applicable) when a counseling discussion is taking place (e.g., a physician prescribing a drug during an office visit, a nurse providing discharge instructions at a hospital, or a pharmacist conveying information at a pharmacy). Patient Information - FDA approved patient labeling. Medication Guide - paper handouts that come with many prescription medicines. The guides address issues that are specific to particular drugs and drug classes, and they contain FDA-approved information that can help patients avoid serious adverse events.

Only NDAs and CDER regulated BLAs are included in this database. ANDAs are not included.

Applications that remain active, even if the product has been discontinued, undergo safety-related labeling changes.

LYTGOBI (NDA-214801)

(FUTIBATINIB)

Safety-related Labeling Changes Approved by FDA Center for Drug Evaluation and Research (CDER)

Download Data

Expand all

10/15/2025 (SUPPL-5)

Approved Drug Label (PDF)

7 Drug Interactions

7.1 Effect of Other Drugs on LYTGOBI

Additions and/or revisions underlined:

Strong CYP3A Inhibitors

Avoid concomitant use of strong CYP3A inhibitors with LYTGOBI.

Futibatinib is a CYP3A substrate [see Clinical Pharmacology (12.3)]. Concomitant use of a strong CYP3A inhibitor increases futibatinib exposure [see Clinical Pharmacology (12.3)], which may increase the risk of adverse reactions.

Strong CYP3A Inducers

Avoid concomitant use of strong CYP3A inducers with LYTGOBI.

Futibatinib is a CYP3A substrate [see Clinical Pharmacology (12.3)]. Concomitant use of a strong CYP3A inducer decreases futibatinib exposure [see Clinical Pharmacology (12.3)], which may reduce the effectiveness of LYTGOBI.

04/17/2024 (SUPPL-2)

Approved Drug Label (PDF)

8 Use in Specific Populations

8.7 Hepatic Impairment

Newly added subsection:

There are limited data in patients treated with LYTGOBI with total bilirubin >1.5 x ULN, and patients with cholangiocarcinoma with total bilirubin >3 x ULN were excluded from enrollment in clinical trials. Patients with cirrhosis and total bilirubin >1.5Í ULN to 3 x ULN may have the potential for increased adverse reactions compared to patients with normal hepatic function due to higher unbound futibatinib exposure [see Clinical Pharmacology (12.3)].